Clearmind Medicine (CMND) reports intranasal MEAI permeation near 98% in study

Rhea-AI Filing Summary

Clearmind Medicine Inc. reported new permeation study data for its proprietary intranasal MEAI (5-Methoxy-2-aminoindane) formulation, part of its program targeting mental-health and metabolic disorders. The study compared intranasal MEAI with a conventional MEAI solution using Franz diffusion cells under physiologically relevant conditions.

Both formulations showed rapid, extensive permeation, with near-complete transport by 180 minutes: 97.35% cumulative permeation for intranasal MEAI versus 98.34% for the conventional solution. This suggests that the formulation’s previously demonstrated enhanced nasal residence time does not materially impair drug transport. Combined with prior ex vivo mucoadhesion data showing substantially longer association with nasal tissue, the company states that these results support continued development of intranasal MEAI as a differentiated therapeutic candidate for conditions such as alcohol use disorder, weight management, obesity, and metabolic diseases. Clearmind also highlights an intellectual property portfolio of nineteen patent families, including 32 granted patents.

Filing Explained

This Form 6-K furnishes Clearmind’s August 11 press release and incorporates its first two paragraphs into listed Form F-3 and Form S-8 registration statements; the filing updates those statements’ disclosure record, but does not report a completed share issuance or sale.

Key Figures

Intranasal MEAI cumulative permeation: 97.35% Conventional MEAI cumulative permeation: 98.34% Permeation study duration: 180 minutes +2 more

5 metrics

Intranasal MEAI cumulative permeation 97.35% Cumulative permeation at 180 minutes for intranasal MEAI formulation

Conventional MEAI cumulative permeation 98.34% Cumulative permeation at 180 minutes for conventional MEAI solution

Permeation study duration 180 minutes Time point at which both formulations achieved near-complete permeation

Patent families nineteen Number of patent families in Clearmind’s intellectual property portfolio

Granted patents 32 Granted patents within Clearmind’s nineteen patent families

Key Terms

mucoadhesion, Franz diffusion cells, neuroplastogen-derived, intranasal drug delivery, +1 more

5 terms

mucoadhesion medical

"recently reported ex vivo mucoadhesion results demonstrating that intranasal MEAI remains associated"

Mucoadhesion is the ability of a drug, medical device or formulation to stick to mucous membranes lining the nose, mouth, throat, eyes or gut, using materials that adhere to wet tissue. For investors it matters because mucoadhesive products can deliver medicine more reliably, extend how long a drug acts, reduce dosing frequency and improve patient convenience—features that can increase a product’s effectiveness, market appeal and commercial value.

Franz diffusion cells medical

"permeation studies were performed using Franz diffusion cells, a widely accepted model"

Laboratory apparatus used to measure how a chemical or drug passes through a barrier, typically skin or a synthetic membrane, over time. Picture a small two-chamber “bathtub” separated by the membrane: one side holds the test formulation and the other collects what diffuses through. Results matter to investors because these measurements inform product performance, formulation decisions, regulatory filings and development timelines, all of which can affect a company’s ability to bring topical or transdermal products to market.

neuroplastogen-derived medical

"non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major"

Neuroplastogen-derived describes a drug or product made from or based on compounds that promote neuroplasticity — the brain’s ability to rewire and form new connections. For investors, this signals a therapy’s intended mechanism of action and market positioning: such treatments aim to repair or improve brain function in conditions like depression or injury, which can mean high clinical and regulatory risk but also potentially large therapeutic value if proven effective.

intranasal drug delivery medical

"two essential attributes for effective intranasal drug delivery"

Intranasal drug delivery is a method of giving medication through the nose so the active ingredient is absorbed across the nasal lining into the bloodstream or, in some cases, more directly into the brain. For investors, it matters because this route can speed onset, avoid breakdown in the digestive system, and enable treatments that would be hard or costly by injection or pills, potentially shortening development time, cutting costs, and opening new market opportunities.

alcohol use disorder (AUD) medical

"candidate for mental-health disorders, including alcohol use disorder (AUD), as well as for weight"

A chronic medical condition in which a person repeatedly drinks alcohol in a way that they cannot control, continuing despite harm to their health, work or relationships; it ranges from risky drinking to severe dependence. Investors should care because AUD drives demand for treatments, public health spending, workplace productivity losses and regulatory attention—similar to how a persistent mechanical problem increases repair and operating costs, it creates long-term market and policy implications for healthcare, insurers and employers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/11/2026 - 04:02 PM Accepted by SEC EDGAR 08/11/2026 - 04:01 PM Learn about SEC filing dates

FAQ

What did Clearmind Medicine (CMND) report about its intranasal MEAI permeation study?

Clearmind reported that intranasal MEAI achieved 97.35% cumulative permeation by 180 minutes, comparable to a conventional MEAI solution at 98.34%. The company states this supports extended nasal residence time without materially impairing drug transport.

How does the intranasal MEAI formulation from CMND compare with a conventional MEAI solution?

In head-to-head permeation testing, both formulations showed rapid, extensive transport, reaching near-complete permeation by 180 minutes. Intranasal MEAI reached 97.35% cumulative permeation versus 98.34% for the conventional formulation, indicating highly comparable permeation behavior.

What therapeutic areas is Clearmind Medicine (CMND) targeting with MEAI?

Clearmind is evaluating MEAI as a differentiated therapeutic candidate for mental-health disorders, including alcohol use disorder (AUD), and for weight management, obesity, and metabolic conditions, using its proprietary intranasal formulation as a potential delivery route.

What experimental model did CMND use to assess intranasal MEAI permeation?

The permeation study used Franz diffusion cells with a cellulose dialysis membrane and simulated nasal electrolyte solution under physiologically relevant conditions. Equivalent MEAI doses were tested as the intranasal formulation and a conventional reference solution to directly compare permeation.

What is the size of Clearmind Medicine’s (CMND) patent portfolio?

Clearmind states that its intellectual property portfolio consists of nineteen patent families, including 32 granted patents. The company plans to seek additional patents when warranted and may acquire further intellectual property to expand this portfolio.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: August 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on August 11, 2026, titled “Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery”.

The first two paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: August 11, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

Exhibit 99.1

Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery

Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, such as addictions and weight-loss, today announced positive permeation study results from its ongoing intranasal MEAI development program.

The new findings confirm that the enhanced nasal residence time previously demonstrated with the proprietary intranasal MEAI formulation does not compromise the permeation characteristics of Clearmind’s proprietary MEAI (5-Methoxy-2-aminoindane).

Clearmind’s early-stage studies of its intranasal MEAI formulation have generated highly promising results, supporting the continued development of this innovative treatment approach. The positive data generated to date supports the company’s development strategy and provide compelling support for the continued advancement of the intranasal program. Together, these findings provide additional support for the continued evaluation of MEAI  as a differentiated therapeutic candidate for mental-health disorders, including alcohol use disorder (AUD), as well as for weight management, obesity, and metabolic conditions. The permeation study builds on recently reported ex vivo mucoadhesion results demonstrating that intranasal MEAI remains associated with nasal tissue substantially longer than a conventional MEAI solution. These findings show markedly enhanced retention of MEAI on nasal mucosa reinforcing its potential to achieve extended nasal residence time within the nasal cavity. Together, the data further supports the continued development of Clearmind’s intranasal program and highlights the formulation’s potential as a differentiated intranasal delivery approach for MEAI. To evaluate whether the enhanced retention of intranasal MEAI influences its release and membrane transport, permeation studies were performed using Franz diffusion cells, a widely accepted model for assessing intranasal drug delivery performance. The experiments used a cellulose dialysis membrane and simulated nasal electrolyte solution under physiologically relevant conditions. Equivalent MEAI doses were applied as either the intranasal formulation or a conventional reference solution, enabling a direct head-to-head comparison of permeation behavior over time. The results showed rapid and extensive permeation for both formulations. While intranasal MEAI displayed a slightly more gradual early-phase release profile, overall permeation was highly comparable to the reference solution. By 180 minutes, both formulations achieved near- complete permeation with cumulative permeation reaching 97.35% for intranasal MEAI and 98.34% for the conventional formulation.

This data indicates that incorporating MEAI into the mucoadhesive intranasal delivery system does not materially impair drug transport. When combined with previously reported mucoadhesion results, the findings suggest that Clearmind’s intranasal strategy may successfully extend nasal residence time while maintaining efficient permeation - two essential attributes for effective intranasal drug delivery.

Together, the results demonstrate three key development achievements supporting the advancement of the intranasal MEAI development program:

● Formulation compatibility: MEAI successfully integrated into the intranasal platform as a stable, fully soluble formulation.

● Enhanced mucoadhesion and prolonged nasal residence: the intranasal MEAI formulation demonstrated substantially longer nasal retention compared with a MEAI saline solution.

● Preserved permeation kinetics: extended residence time was achieved without compromising MEAI transport across the tested membrane.

“These results represent an important milestone in our efforts to advance MEAI as a differentiated therapeutic candidate for alcohol use disorder,” said Dr. Adi Zuloff Shani, Chief Executive Officer of Clearmind Medicine. “The significantly enhanced nasal retention demonstrated by intranasal MEAI underscores the  potential advantages of intranasal delivery as a promising administration route for MEAI. We are encouraged by the formulation’s ability to maintain prolonged contact with nasal tissue while demonstrating permeation characteristics comparable to a conventional MEAI formulation, and believe these findings further support the overall development program.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical studies, the company’s development strategy, the continued advancement of the intranasal program and advancing MEAI as a differentiated therapeutic candidate for alcohol use disorder. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Investor Relations:

invest@clearmindmedicine.com

www.Clearmindmedicine.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES POSITIVE PERMEATION RESULTS 15.4 KB